Comparative Pharmacology
Head-to-head clinical analysis: MALARONE versus SOVUNA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MALARONE versus SOVUNA.
MALARONE vs SOVUNA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atovaquone is a selective inhibitor of the mitochondrial electron transport chain at the cytochrome bc1 complex (Complex III), disrupting pyrimidine synthesis and ATP generation in Plasmodium species. Proguanil, via its metabolite cycloguanil, inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis. Synergistic activity against erythrocytic and exoerythrocytic stages.
SOVUNA (suvorexant) is a dual orexin receptor antagonist that blocks the binding of orexin neuropeptides to orexin OX1 and OX2 receptors, thereby promoting sleep initiation and maintenance.
For malaria treatment: 4 tablets (each containing atovaquone 250 mg/proguanil 100 mg) orally once daily for 3 consecutive days. For malaria prophylaxis: 1 tablet (atovaquone 250 mg/proguanil 100 mg) orally once daily starting 1-2 days before travel, continued during travel and for 7 days after leaving endemic area.
400 mg orally once daily with food.
None Documented
None Documented
Atovaquone: 50-70 hours (mean ~60 h); proguanil: 12-21 hours (mean ~16 h); cycloguanil: 10-16 hours. Long half-life of atovaquone allows single-dose treatment, but may delay parasite clearance.
Terminal half-life 14 hours; clinically significant for once-daily dosing, requiring dose adjustment in renal impairment (CrCl <30 mL/min).
Atovaquone: 94% excreted unchanged in feces via biliary elimination, 6% in urine. Proguanil: 40-60% excreted unchanged in urine; cycloguanil (active metabolite) and proguanil metabolites also cleared renally.
Primarily renal (70% unchanged) and 20% fecal via bile; minor metabolic clearance.
Category C
Category C
Antimalarial
Antimalarial